Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: Implications for pretransplant conditioning

被引：0
|
作者：
Fruehauf, S [1 ]
Topaly, J [1 ]
Schad, M [1 ]
Ho, A [1 ]
Zeller, W [1 ]
机构：
[1] Univ Heidelberg, D-6900 Heidelberg, Germany
来源：
EXPERIMENTAL HEMATOLOGY | 2002年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
224
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [21] Periungual Pyogenic Granuloma Following Imatinib Therapy in a Patient With Chronic Myelogenous Leukemia
    Dika, Emi
    Barisani, Alessia
    Vaccari, Sabina
    Fanti, Pier Alessandro
    Ismaili, Alma
    Patrizi, Annalisa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (05) : 512 - 513
  • [22] Treatment of imatinib-sensitive and -resistant chronic myelogenous leukemia cells with a combination of imatinib and farnesyltransferase inhibitors.
    Radujkovic, A
    Topaly, J
    Zeller, WJ
    Ho, AD
    Fruehauf, S
    BLOOD, 2005, 106 (11) : 300B - 300B
  • [23] The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
    Sneed, TB
    Kantarjian, HM
    Talpaz, M
    O'Brien, S
    Rios, MB
    Bekele, BN
    Zhou, M
    Resta, D
    Wierda, W
    Faderl, S
    Giles, F
    Cortes, JE
    CANCER, 2004, 100 (01) : 116 - 121
  • [24] Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
    Kantarjian, HM
    Bueso-Ramos, CE
    Talpaz, M
    O'Brien, S
    Giles, F
    Faderl, S
    Wierda, W
    Rios, MB
    Shan, JQ
    Cortes, J
    CANCER, 2005, 104 (04) : 777 - 780
  • [25] Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials
    Guilhot, F
    Gardembas, M
    Rousselot, P
    Tulliez, M
    Vigier, M
    Buzyn, A
    Rigal-Huguet, F
    Legros, L
    Michallet, M
    Berthou, C
    Najman, A
    Maloisel, F
    Mahon, FX
    Facon, T
    Berthaud, P
    Guilhot, J
    SEMINARS IN HEMATOLOGY, 2003, 40 (02) : 92 - 97
  • [26] In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia
    La Rosée, P
    Johnson, K
    O'Dwyer, ME
    Druker, BJ
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (07) : 729 - 737
  • [27] Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia
    Uchiyama, Michihiro
    Ikeda, Takashi
    LEUKEMIA RESEARCH, 2009, 33 (12) : 1723 - 1724
  • [28] Central nervous system (CNS) leukemia after imatinib mesylate therapy for chronic myelogenous leukemia (CML)
    Solh, M. M.
    Kantarjian, H.
    O'Brien, S.
    Giles, F.
    Faderl, S.
    Garcia-Manero, G.
    Rios, M.
    Shan, J.
    Cortes, J.
    Ravandi-Kashani, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
    Bueso-Ramos, CE
    Cortes, J
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Medeiros, LJ
    Kantarjian, H
    CANCER, 2004, 101 (02) : 332 - 336
  • [30] Interstitial lung disease associated with imatinib (Gleevec) therapy for chronic myelogenous leukemia (CML).
    Donna, E
    Ahn, YS
    Huang, HS
    Horstman, LL
    Jimenez, JJ
    Jy, WC
    BLOOD, 2002, 100 (11) : 327B - 327B
12345